Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Equipped with state-of-the-art facilities and experienced immunology experts, Creative Biolabs has expanded its service capabilities to offer a fully integrated CAR-T Cell Display Platform. This new platform will accelerate the timeline for cell and gene therapy development to best suit your program requirements.
Chimeric antigen receptor (CAR) T cell therapies have achieved considerable progress in clinical cancer immunotherapy. However, safety challenges remain. A major problem is the response that CARs to an antigen present on healthy cells (on-target, off-tumour response). One effective strategy to improve this situation is to design the affinity of CARs so that they are activated only by tumor cells expressing high antigen levels.
Over years, Creative Biolabs has established a unique CAR-T cell display platform that enables the engineering of variants based on antigen binding and/or signaling-based screening. By using the CRISPR-Cas9 genome editing system, we have generated an antigen-binding domain variants library with different binding affinity. Through several rounds of functional screening and deep sequencing guided selection, CAR variants selectively activated by tumor cells were distinguished based on antigen expression level. What is more, the green fluorescence reporter (GFP) reporter gene can be integrated downstream of the endogenous interleukin-2 (IL-2) gene to facilitate high-throughput screening of activated T cells by fluorescence-activated cell sorting (FACS).
Creative Biolabs' scientists are dedicated to bringing together years of valuable experience to help our clients shorten the clinical study journey. We are committed to providing CAR-T display platform to reduce the overall project development timeline for our clients. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
